Tailstorm Health Inc.
Tailstorm Health Inc. is a 503B outsourcing facility based in Phoenix, AZ. A government record names semaglutide and tirzepatide at Tailstorm Health Inc.; the newest is an FDA inspection report (Form 483) dated November 14, 2025. It fills prescriptions; it doesn’t write them, so you can’t get a GLP-1 from Tailstorm Health Inc. without a prescription from a licensed clinician.1
How to get a GLP‑1 filled by Tailstorm Health Inc.Checked November 20, 2026 against FDA, CMS and state board records. Every fact links to its source.
Tailstorm Health Inc. at a glance
How to get a GLP‑1 filled by Tailstorm Health Inc.
To get a GLP‑1 from Tailstorm Health Inc., you first need a prescription: it fills prescriptions; it doesn’t write them or sell without one. An online program takes you through the steps: you fill in a health questionnaire, a licensed clinician reviews it, and if they prescribe, the program’s pharmacy ships the medication to you.
These are the three programs ranked highest on our score. Check that a program ships to your state before you sign up.
- 1Health questionnaire, online
- 2A licensed clinician decides
- 3The pharmacy ships to you
We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money
Prefer your own clinician? You’re free to: ask them to send your prescription to Tailstorm Health Inc. or another licensed pharmacy.
See every program we rankWhat ties Tailstorm Health Inc. to GLP‑1s
- FDA inspection report (Form 483)November 14, 2025 · semaglutideFDA Form 483 inspectional observations, Tailstorm Health, Inc., issued 2025-11-143
“tirzapetide pre-filled syringes, and semaglutide pre-filled”
- FDA warning letterApril 8, 2025 · semaglutide and tirzepatideFDA warning letter WL # 703497 to Tailstorm Health, Inc.4
“Your facility’s drug products, such as Semaglutide Injection 1mg/0.2ml and Tirzepatide Injection 2.5mg/0.5ml, did not include the following on the label”
- FDA inspection report (Form 483)October 10, 2024 · semaglutideFDA Form 483 inspectional observations, Tailstorm Health, Inc., issued 2024-10-105
“during the assembly of the filling machine for Semaglutide (8mg/mL)”
Tailstorm Health Inc.’s FDA record
| Date | What the FDA did |
|---|---|
| August 28, 2026 | 483 Issued 08/28/20266 |
| March 23, 2026 | Warning Letter Close Out Issued 03/23/20267 |
| March 20, 2026 | FMD-145 Letter Issued 03/20/2026 |
| March 19, 2026 | FMD-145 Letter Issued 03/19/2026 |
| November 14, 2025 | 483 Issued 11/14/20258 |
| May 23, 2025 | 483 Issued 05/23/20259 |
| April 8, 2025 | Warning Letter Issued 04/08/20254 |
| October 10, 2024 | 483 Issued 10/10/202410 |
| October 23, 2023 | FMD-145 Letter Issued 10/23/2023 |
| June 17, 2022 | Untitled Letter Issued 06/17/202211 |
| July 21, 2021 | 483 Issued 07/21/202112 |
What a compounded GLP‑1 is, and what it isn’t
The bigger question with any compounded program is the drug itself. Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.1617 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.1513
Tailstorm Health Inc.: questions
- 1.NPI Registry: TAILSTORM HEALTH LLC (NPI 1548370497)Centers for Medicare & Medicaid Servicesretrieved 2026-11-20↩
- 2.Registered Outsourcing FacilitiesU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 3.FDA Form 483 inspectional observations, Tailstorm Health, Inc., issued 2025-11-14FDAretrieved 2025-11-14↩“tirzapetide pre-filled syringes, and semaglutide pre-filled”
- 4.FDA warning letter WL # 703497 to Tailstorm Health, Inc.FDAretrieved 2025-04-08↩“Your facility’s drug products, such as Semaglutide Injection 1mg/0.2ml and Tirzepatide Injection 2.5mg/0.5ml, did not include the following on the label”
- 5.FDA Form 483 inspectional observations, Tailstorm Health, Inc., issued 2024-10-10FDAretrieved 2024-10-10↩“during the assembly of the filling machine for Semaglutide (8mg/mL)”
- 6.FDA: 483 Issued 08/28/2026 (PDF - 9.53MB)U.S. Food and Drug Administration↩
- 7.FDA: Warning Letter Close Out Issued 03/23/2026U.S. Food and Drug Administration↩
- 8.FDA: 483 Issued 11/14/2025U.S. Food and Drug Administration↩
- 9.FDA: 483 Issued 05/23/2025 (PDF - 1.27 MB)U.S. Food and Drug Administration↩
- 10.FDA: 483 Issued 10/10/2024 (PDF - 1.18 MB)U.S. Food and Drug Administration↩
- 11.FDA: Untitled Letter Issued 06/17/2022 (PDF - 404 KB)U.S. Food and Drug Administration↩
- 12.FDA: 483 Issued 07/21/2021 (PDF - 1 MB)U.S. Food and Drug Administration↩
- 13.Compounding inspections, recalls, and other actionsU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 14.Arizona license lookupazbop.igovsolution.net↩
- 15.Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration↩
- 16.
- 17.
A pharmacy’s record can change after the day we read it: check its license with its state board before you fill a prescription. An FDA document is an allegation or an observation the FDA has published, not a court finding. This page is educational and is not medical advice.